Scienture Holdings Inc. (SCNX), a holding company for pharmaceutical companies, announced on Wednesday a third patent for the Arbli oral suspension or Losartan potassium in treating hypertension, granted by the U.S. patent and trademark office or USPTO.
Arbli is an angiotensin receptor blocker or ARB, formulated as an oral suspension for administration to pediatric and geriatric patients, and other patient populations facing difficulties in swallowing. It is the first oral liquid suspension for the treatment of hypertension and was approved in March 2025 by the U.S. food and drug administration.
The patent was granted on April 21 and will provide intellectual property protection and market exclusivity till October 7, 2041.
SCNX is trading at $0.41, up 5.54%.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.